Table 2 Clinical and pathological characteristics of an additional series of 112 primary tumors presenting HRPFs.
Characteristics | Metastatic (n = 19) | Non-metastatic (n = 93) | p-value |
|---|---|---|---|
Laterality n (%) | |||
Unilateral | 14 (73.7%) | 70 (75.3%) | 0.8844a |
Bilateral | 5 (26.3%) | 23 (24.7%) | |
Age at diagnosis (months) | |||
Median (range) | 31 (10–88) | 31 (1–168) | 0.9166b |
Initial treatment n (%) | |||
Enucleation | 15 (78.9%) | 91 (97.8%) | 0.007394c |
Pre-enucleation chemotherapy | 4 (21.1%) | 2 (2.2%) | |
IRSS Stage I HRPF | |||
Isolated massive choroidal invasion (+ scleral invasion) | 4 (1) (21%) | 7 (6) (7.5%) | 0.0312c |
Post-laminar optic nerve invasion (+ massive choroidal and/or scleral invasion) | 9 (3) (47.4%) | 83 (49) (89.3%) | |
IRSS Stage II | |||
Tumor at the resection margin of the optic nerve | 5 (26.3%) | 3 (3.2%) | 0.003428c |
IRSS not classified | |||
Complete necrosis | 1 (5.3%) | 0 | |
Site of metastatic relapse | |||
Isolated orbit | 3 (15.8%) | ||
CNS | 6 (31.6%) | ||
Systemic | 1 (5.3%) | N/A | |
Orbit and lymph node | 1 (5.3%) | ||
Orbit and systemic relapse | 3 (15.8%) | ||
Orbit and CNS | 5 (26.3) |
